Inhibition of gelatinase activity by cyclic peptides-A support for oral cancer treatment?

Oral Oncology

Volumn 42, Issue 10, 2006, Pages 955-956

  Salo, Tuula ^a   Sorsa, Timo ^b   Lindqvist, Christian ^b  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPEPTIDE; CYSTEINYLTHREONYLTHREONYLTRYPTOPHYLGLYCYLPHENYLALANYLTHREONYLLEUCINE; DOXORUBICIN; GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; GLYCYLARGINYLGLUTAMYLASPARAGINYLTYROSYLHISTIDYLGLYCYLCYSTEINYLTHREONYL THREONYLHISTIDYLTRYPTOPHYLGLYCYLPHENYLALANYLTHREONYLLEUCYLLEUCINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; KAPOSI SARCOMA; METASTASIS; MOUTH CANCER; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

ANIMALS; ENZYME INHIBITORS; GELATINASES; MICE; MOUTH NEOPLASMS; PEPTIDES, CYCLIC;

EID: 33750000538     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2005.12.015     Document Type: Editorial

References (12)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 (1999) 827-841
2. Kari S., Alho O.p., Jokinen K., Hyrynkangas K., and Läärä E. Carcinoma of the tongue in northern Finland. Trends in overall incidence and patient and tumour characteristics. Oral Pathol Med 26 (1997) 480-483
3. Björklund M., and Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755 (2005) 37-69
4. Sorsa T., Tjäderhane L., and Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Diseases 10 (2004) 311-319
5. Ruokalainen H., Pääkkö P., and Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 10 (2004) 3110-3116
6. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical application of research on angiogenesis. N Engl J Med 333 (1995) 1757-1763
7. Folkman J. Angiogenesis zip code. Editorial. Nat Biotechnol 17 (1999) 749
8. Koivunen E., Arap W., Valtanen H., et al. Tumor targeting with a selective gelatinases inhibitor. Nat Biotechnol 17 (1999) 768-774
9. Medina O.P., Söderlund T., Laakkonen L.J., Tuominen E.K.J., Koivunen E., and Kinnunen P.K.J. Binding of novel inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res 61 (2001) 3978-3985
10. Heikkilä P, Suojanen J, Pirilä E, et al. Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. Int J Cancer, in press.
11. Balbin M., Fuey A., Tester A.M., et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 35 (2003) 252-257
12. Agarwal D., Goodison S., Nicholson B., et al. Expression of MMP-8 and TYRP-1 correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation 71 (2003) 114-125